The position of Stephens Inc. AR lowered in the BioMarin Pharmaceutical Inc.

The position of Stephens Inc. AR lowered in the BioMarin Pharmaceutical Inc.

According to the company in its latest 13F filing with the SEC, Stephens Inc. AR sank its position in the BioMarin Pharmaceutical Inc. by 4.8 percent in the 1st quarter. The institutional investor has the possession of 3,274 shares of the biotech company’s stock after vending 166 shares during the period. In its most recent SEC filing, Stephens Inc. AR’s position in the BioMarin Pharmaceutical was worth $291,000.

Various other investors recently either reduced or added to their stakes in the biotech company’s stock.  Doyle Wealth Management raised its position in the BioMarin Pharmaceutical during the fourth quarter which can be valued at approximately $26,000. Commonwealth Bank of Australia raised its holdings in the biotech company’ stock by 49.6 percent during the fourth quarter. Commonwealth Bank of Australia has now the possession of 350 shares of the biotech company’s stock valued at $29,000 after buying an extra 116 shares in the last quarter. Lindbrook Capital LLC raised its position in the BioMarin Pharmaceutical during the fourth quarter valued at approximately $30,000. PRW Wealth Management LLC also raised its position in the biotech company’s stock during the fourth quarter valued at approximately $30,000. Lastly, Lake Point Wealth Management raised its holding in the BioMarin Pharmaceutical during the fourth quarter valued at approximately $34,000. 98.48% of the company’s stock is owned by various institutional investors.

A various number of reports of analysts have been issued on the company. ValuEngine lowered the BioMarin Pharmaceutical to a holding rating from a “buy” rating in a report on the 20th of February, Wednesday. Robert W. Baird set a target price of $120 on the BioMarin Pharmaceutical and gave the ‘Buy’ rating to the stock in a report published on the 22nd of April, Tuesday.

 

.